AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04622579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide combined with rituximab
Description: lenalidomide and rituximab are dilivered as described, parameters concerning efficacy and safety are also obtained.
Study NCT03212105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 60 Second Video
Description: The mindfulness intervention will be a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
Study NCT03960918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise therapy
Description: aerobic exercise therapy: All enrolled subjects will perform a CPET before the training initiation. After CPET, the patients in the experimental group need to perform an additional bicycle training program with the intensity of 60 % maximal workload in the previous CPET (five days per week, for four weeks with a total of 20 times).
Study NCT02088528 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aurolab glaucoma drainage device
Description: Patients undergoing surgery will receive an implant
Study NCT02088528 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy with mitomycin-c
Description: Trabeculectomy surgery augmented by application of mitomycin C (0.4 mg/ml) to the sclera in the region of the trabeculectomy site for a period of exactly 3 minutes.
Study NCT03325647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution
Description: Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.
Study NCT03325647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo injectable saline
Description: Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.
Study NCT03495193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Exercise training will be performed 3x/week. After 2 sessions, training volume and intensity will progress over the first 4 sessions ramping up the number of sets to increase the volume. The full volume prescription will consist of: 1) 5 movements to improve strength and muscle mass (leg press, knee extension, chest press, overhead press, pull down), 3 sets each of 8-12 repetitions (\~30 total repetitions); 2) trunk exercises to improve postural stability (trunk extension and flexion); 3) 3-4 bodyweight exercises (selected from a menu) to improve power and balance (e.g. step up, squat, jump squat, lunge, side lunge, push-up, assisted pull-up, assisted dip). Bodyweight movements will be modified as necessary to match abilities.
Study NCT03495193 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene
Description: Subjects randomized to the no-exercise group will receive a handout with tips for improving sleep. Additionally, study staff will provide the title page for a book on sleep relaxation techniques that is recommended for persons with sleeping difficulty. Dr. Amara will review the sleep tips with the subjects and make recommendations for improving current sleep habits. Subjects will be contacted by telephone every 4 weeks during the 16-week intervention period.
Study NCT04312659 — intervention group
Intervention type: DRUG
Intervention: Infliximab
Description: Participants will be observed who were treated with Infliximab.
Study NCT03619499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non invasive ventilation
Description: patients who will fulfill the criteria of severe bronchiolitis will be connected to non invasive ventilation including continuous positive airway pressure via nasal prongs or nasal mask. Mode of ventilation, inspired oxygen levels, oxygen saturation, respiratory rate, and blood gas values from arterial samples prior to and after 2 and 4 hrs of ventilation or nearest time, will be documented.
Study NCT03988725 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Vitamin E 800 IU once daily
Study NCT01357356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER120 (750 ng/day)
Study NCT01357356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER120 (1000 ng/day)
Description: SER120 (1000 ng/day)
Study NCT01357356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER120 (1500 ng/day)
Study NCT01357356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00352079 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG vaccine
Description: Intravesical BCG:~Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months post- 2 randomization (cycles 2 - 8)
Study NCT00352079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gefitinib
Description: Iressa® 250 mg PO Daily for 12 weeks starting on day 1 of each cycle of intravesical BCG therapy (cycles 1 - 8)
Study NCT00352079 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Each cycle and at 3 and 6 months after treatment discontinuation
Study NCT01097356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic drinkers
Description: HPV+, LSIL patients in this arm will drink the probiotic study drink for a period of 6 months
Study NCT02647554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulinastatin
Description: ulinastatin 400,000 IU every 8 hours for 10 days
Study NCT02647554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo every 8 hours for 10 days
Study NCT02804269 — intervention group
Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance
Description: For the evaluation of heart function and structure of the cardiovascular system.
Study NCT02804269 — intervention group
Intervention type: OTHER
Intervention: Fatmass measurement
Description: It utilizes a scale machine to measure the body fat and skeletal muscle percentage
Study NCT03476915 — intervention group
Intervention type: OTHER
Intervention: ultrasound examination of the hip joint
Description: US examination by US machine , Midray model DP-2200 made in China , with a high frequency (5-10 MHZ) linear transducer using the previously described Graf method for assessment of both hip joints.
Study NCT02880072 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phosphate orally
Description: 4 different preparations of phosphate
Study NCT05175079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupressure band
Description: acupressure band apply to P6 (nei guan) point which located three fingers below the skin wrinkles of the anterior wrist.~Acupressure band wear 3 times daily before breakfast, lunch and dinner for at least 10 minutes
Study NCT05175079 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment hospital protocol
Description: Intravenous metaclopromide 10mg PRN Intravenous fluids as per protocol
Study NCT02038478 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Stem Cell Transplantation
Description: One day after they complete their radiation and Campath-1H treatments and have begun their Sirolimus, the donor blood stem cells described above are transfused through the central line. This process takes approximately 30 minutes to 2 hours and is normally completely without side effects.
Study NCT02297906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Non-steroidal anti-inflammatory drug
Study NCT02297906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Non-steroidal anti-inflammatory drug
Study NCT03776851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin
Description: erythropoietin 50 International Units (IU) per kilogram three times weekly by subcutaneous route
Study NCT03105115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: intrathecal fentanyl will be added as adjuvant for spinal anesthesia using heavy bupivacaine, while dexmedetomidine will be infused intravenously during operation
Study NCT03105115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine only
Description: heavy bupivacaine will be injected intrathecally during spinal anesthesia, without fentanyl, while dexmedetomidine will be infused intravenously during operation
Study NCT02615327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 8 g Polydextrose
Description: 8g of Polydextrose
Study NCT02615327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 12 g Polydextrose
Description: 12 g of Polydextrose
Study NCT02615327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 16 g Polydextrose
Description: 16 g of Polydextrose
Study NCT02615327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 g of Polydextrose
Study NCT01963819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy
Description: The endometrial biopsy will be done in the luteal phase (cycle day 18-22) prior to the treatment cycle (antagonist)
Study NCT00732329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: optimized home Based Occupational Therapy including:~* diagnostic assessment~* patient-centered definition of targets involving the care giver~* occupational therapy
Study NCT00600288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diquafosol tetrasodium Ophthalmic Solution, 2%
Description: 1-2 drops administered in each eye 4 times a day for 6 weeks
Study NCT00600288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-preserved saline solution (Placebo)
Description: 1-2 drops administered in each eye 4 times a day for 6 weeks
Study NCT00782236 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Graft Material
Description: After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of Straumann Bone Ceramic or Freeze Dried Allograft Bone (FDBA) with a resorbable collagen membrane (Bio-Gide) for preservation of the alveolar ridge following tooth extraction. Following 6 months of healing, a core of bone will be taken from the surgical site and a dental implant will be placed. The subjects will then be followed for 12 months following dental implant placement.
Study NCT02451670 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prioritized Clinical Decision Support
Description: After entry of blood pressure data at all primary care visits, relevant electronic health record data were automatically extracted, encrypted and processed through Web-based clinical algorithms that determined if the patient met intervention eligibility criteria. In intervention clinics, the rooming staff received a best practice alert and printed patient and primary care provider versions of the clinical decision support that identified evidence-based treatment options for any uncontrolled cardiovascular risk factors and prioritized treatment recommendations based on potential cardiovascular risk reduction. Cardiovascular risk factors addressed in study participants were control of lipids, blood pressure, weight, tobacco, glucose and appropriate aspirin use. In control clinics, rooming staff did not receive a best practice alert and patients and primary care providers did not receive and were not able to access the clinical decision support.
Study NCT03229993 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OCT
Description: OCT is used to assess whether PCI will be of benefit to the treatment of the borderline coronary artery lesions
Study NCT02110758 — intervention group
Intervention type: OTHER
Intervention: Pilot of Patient-Centered Oncology Care
Description: Patient-Centered Oncology Care addresses six domains: track \& coordinate referrals, provide access and communication, identify and coordinate patient populations, plan and manage care, track \& coordinate care, and measure and improve performance.
Study NCT04084951 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SQZ-PBMC-HPV
Description: antigen presenting cell therapy; therapeutic vaccine consisting of peripheral blood mononuclear cells (PBMCs) manufactured with immunogenic epitopes of HPV16
Study NCT04084951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: programmed cell death ligand 1 (PD-L1) blocking antibody
Study NCT04084951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody
Study NCT04084951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: programmed cell death 1 (PD-1) blocking antibody
Study NCT02755103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Relapse Prevention (MBRP)
Description: MBRP integrates coping skills from cognitive-behavioral relapse prevention therapy with Mindfulness Meditation (MM) practices, raising awareness of substance use triggers and reactive behavioral patterns, and teaching skillful coping responses.
Study NCT03989128 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Undergo medical chart review
Study NCT03989128 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study NCT04104503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF11167
Description: Lu AF11167 - 2 mg modified release tablets (reference formulation), up to 5 prototype MR tablet formulations (test formulations)
Study NCT04104503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Lu AF11167
Description: single iv microdose administered as a 15 minutes infusion
Study NCT04104503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF11167 MR tablet prototype formulation selected from part A or 1 mg modified release tablet (reference formulation)
Description: Single oral dose
Study NCT05468294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F16IL2
Description: F16IL2 infusion will be always administered in 180 minutes i.v. on day 1, 8, 15 and 22 of each 28-days cycle.
Study NCT05468294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab, fixed dose
Description: Patients will receive 3 mg/kg of Nivolumab as a 60 minutes i.v. infusion on day 1 and day 15 of each 28-days cycle.
Study NCT02097329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palbociclib commercial free base
Description: 125 mg oral capsule single dose
Study NCT02097329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famotidine
Description: 20 mg oral tablet 10 hours before and 2 hours after palbociclib
Study NCT02097329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: 2 x 20 mg oral tablets daily for 6 days then on 7th day, 4 hours after palbociclib
Study NCT03535493 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy (ACT)
Description: An ACT session entails a mindfulness-based training to foster and nurture effective behavioral and emotional responding to distress.
Study NCT02097329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antacid
Description: 30 mL orally once (2h before palbociclib)
Study NCT02097329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antacid
Description: 30 mL orally once (2h after palbociclib)
Study NCT01706341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: administer acetate Ringer's solution
Description: During cesarean section under spinal anesthesia, each acetate Ringer's solution is administered before delivery.
Study NCT01706341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetate Ringer's solution containing no glucose
Study NCT01706341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetate Ringer's solution containing 1% glucose
Study NCT01129063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Pharmaceutical form : tablet~Route of administration: oral
Study NCT02791919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT
Study NCT02791919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV or SC
Study NCT02791919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT02791919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02791919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02791919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WEE1 Inhibitor AZD1775
Description: Given PO
Study NCT02114424 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positional vibrator belt
Description: Belt with vibarator to avoid sleep supine
Study NCT02259374 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP BLOCK 0.2% ROPIVACAINE
Description: Patients randomised to this group will receive 20 ml 0.2% Ropivacaine for bilateral TAP block after hysterectomy
Study NCT02259374 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP BLOCK 0.4% ROPIVACAINE
Description: Patients randomised to this group will receive 20 ml 0.4% Ropivacaine for bilateral TAP block after hysterectomy
Study NCT01567774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: os, 20 mg, once per day, for 30 days
Study NCT01735045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lagado LSH (mangofilcon A) Soft (hydrophilic) Contact Lens
Description: Daily Wear
Study NCT01735045 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens
Study NCT03535493 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Float REST
Description: A float session entails laying supine in a light-proof, sound-proof tank consisting of a shallow pool of water (approximately 10 inches set to approximately 94.5 degrees to match skin temperature) with a high concentration of Epsom salt (approximately 1200 pounds) for 60 minutes.
Study NCT03535493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT + Float REST
Description: The combined intervention will combine ACT and Float REST. An ACT session entails a mindfulness-based training to foster and nurture effective behavioral and emotional responding to distress. A float session entails laying supine in a light-proof, sound-proof tank consisting of a shallow pool of water (approximately 10 inches set to approximately 94.5 degrees to match skin temperature) with a high concentration of Epsom salt (approximately 1200 pounds) for 60 minutes.
Study NCT01047306 — intervention group
Intervention type: OTHER
Intervention: assessment
Description: Physical, developmental, neurological, behavioral, and neurocognitive assessments
Study NCT02974374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06835919
Description: Single or repeated, escalating dose
Study NCT02974374 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single or repeated, escalating dose
Study NCT00586300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training program
Description: The physical training will be completed in two phases. In Phase 1, which will last 9 months, participants will complete the program under the supervision of an experienced trainer. Sessions will occur three times each week in a designated study facility. The program will include the following components: stretching and balance, flexibility and range of motion, muscle strengthening, and aerobics. The program will also emphasize the importance of individualizing exercise regimens according to each person's specific needs (function and fitness). In Phase 2, the primary objective will be to promote long-term exercise (for up to 24 months from the time of study entry) that incorporates the four modalities of exercise instruction introduced in Phase 1, but on an independent basis.
Study NCT00586300 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-management training program
Description: The self-management training program is designed to target primarily coping skills and self-efficacy. This will be accomplished by using a variety of educational and behavioral methods. The program will be delivered in two phases. The initial 9-month phase will consist of 12 weekly 60-minute classroom sessions, followed by 24 weeks of a structured telephone intervention program. Phase 2 will continue to incorporate the telephone intervention program, at less frequent intervals, for up to 24 months from the time of study entry.